Drug Development

Feliza Mirasol is the science editor for 

Articles

The EMA’s Committee for Medicinal Products for Human Use has given a positive opinion on Sandoz’ biosimilar trastuzumab for breast and gastric cancer.

EMA Committee Issues Positive Opinion on Sandoz’ Biosimilar Trastuzumab

Colorcon provides customers with Opadry complete film coating systems, which intends to help reduce complexity with delivering high-quality products and ingredients.

Colorcon Launches New Titanium Dioxide Free Moisture Protection Coating for Pharmaceutical Tablets

Excipients should be treated equally when it comes to quality management, risk assessment, and testing.

In Equal Measures: The Importance of Excipient Quality

Cynthia A. Challener is a contributing editor to Pharmaceutical Technology.

Coprocessed excipients save time and cost while improving performance in a widening array of dosage forms.

Formulating with Coprocessed Excipients: Current Trends

The collaboration partner for Willow is focused on more sustainable methods to manufacture intermediates and APIs at reduced cost and less waste, in addition to looking for Willow’s expertise in developing and scaling key ingredients. 

Willow Biosciences Announces Collaboration with Biopharma Company 

The deal is worth up to $36 million with an initial upfront consideration of $14 million, with an additional $22 million in contingent value rights (CVRs) that is payable upon achieving certain milestones.

LEO Pharma to Acquire Timber Pharmaceuticals

FDA has halted enrollment in clinical studies for Gilead Sciences’ magrolimab, a biologic treatment in development for acute myeloid leukemia.

FDA Halts Clinical Trial Enrollment for Gilead’s Magrolimab in AML Studies

Felicity Thomas is the former Associate Editorial Director of Pharmaceutical Technology, Pharmaceutical Technology Europe, BioPharm International.

Podcasts

In this episode, David Tisi and Reenal Gandhi provide expert insights into advances and innovations changing the drug dosage form landscape.

Drug Solutions Podcast: Innovations and Advances in Drug Dosage Forms

Teva Pharmaceuticals and Alvotech will expand their partnership for the development and commercialization of biosimilar candidates.

Teva Pharmaceuticals and Alvotech Expand Existing Biosimilars Partnership

Janssen has received a positive opinion from the EMA for two novel bispecific antibodies, TALVEY (talquetamab) and TECVAYLI (teclistamab), which the company is developing to treat blood cancer.

APIs and Excipients